Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank
Mandate

Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank

March 04, 2025 M&A Financial Regulatory

The partnership between SpareBank 1 Markets and Swedbank aims to create a leading Nordic investment bank. As part of the transaction, SpareBank 1 Markets will receive Swedbank’s Corporate Finance and DCM High-Yield business in Sweden and establish a branch in Stockholm through which the business operations will be conducted.

Pursuant to the partnership, Swedbank will become part-owner of SpareBank 1 Markets with a 20% stake thereby strengthening the position of both banks in the Nordic market and creating new opportunities for expansion in investment banking.

The transaction is subject to regulatory approvals and customary closing conditions.

Vinge’s team primarily consists of Samra Tesser, Nils Unckel, Anton Sjökvist and Gustav Wahlberg.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026